secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001570562-24-000127
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M
-------------------------------------------------------------------------

- Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.
- Full-year 2024 revenue guidance narrowed to $260-266M (29-32% YoY growth).
- Received EU approval for Estyme HA gels; U.S. PMA for Evolysse under FDA review, launch expected by Sep 2025.
- Evolus Rewards loyalty program exceeded 1M enrolled consumers and 2M total redemptions.
- Reaffirms positive non-GAAP operating income target for Q4 2024 and full year 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/0001570562-24-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056224000127/eols-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001570562-24-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer